This is a pipeline-expansion signal with no near-term revenue or clinical data catalyst. Monitor for any in vivo study initiation announcement or TNBC enrollment updates, which would be more material events. The stock's historical reaction to similar neutral filings has been mixed, with no clear directional pattern.
Price Chart
Executive Summary
Telomir Pharmaceuticals announced preclinical in-vitro data from Ohio State University showing Telomir-Zn inhibits cell growth across human and canine osteosarcoma cell lines. The company's lead TNBC program continues advancing toward Phase 1/2 enrollment, while the osteosarcoma findings open a potential parallel development pathway in canine models. This is an early-stage preclinical data release with no financial impact or timeline for the osteosarcoma program, making it a modest positive for pipeline optionality but not a near-term catalyst.
Key Facts
- Preclinical study demonstrated dose-dependent growth inhibition of Telomir-Zn across three osteosarcoma cell lines: HOS (human), D17 (canine), and Abrams (canine).
- All three cell lines showed growth inhibition at similar low drug concentrations.
- TNBC Phase 1/2 program is advancing toward site initiation and patient enrollment under an active FDA-cleared IND.
- Company is in discussions with Ohio State for a potential in vivo efficacy study in canine osteosarcoma.
- No financial data, guidance, or enrollment timelines were provided in the filing.
Financial Impact
No financial figures reported; preclinical data only.
Risk Factors
- Preclinical in-vitro results may not translate to in vivo efficacy or clinical benefit.
- Osteosarcoma program is exploratory and may not be pursued if TNBC program requires full capital allocation.
- Company is clinical-stage with no approved products or revenue, carrying typical development and financing risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-042483 |
| Exhibit: ex99-1.htm | 0001493152-26-042483 |
| Document: 0001493152-26-042483-index-headers.html | 0001493152-26-042483 |
| Document: 0001493152-26-042483-index.html | 0001493152-26-042483 |
| Document: 0001493152-26-042483.txt | 0001493152-26-042483 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $1.20 | awaiting T+20 | — | $0.9985 (−16.79%) |
Sep 17, 2026 5w ago | 8-K | $1.12 $1.05 | ▼ −6.25% | ▼ −7.46% | $0.9985 (−10.85%) |
Sep 17, 2026 5w ago | Press Release | $1.12 $1.05 | ▼ −6.25% | ▼ −7.71% | $0.9985 (−10.85%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $1.10 | ▼ −5.98% | ▼ −8.25% | $0.9985 (−14.66%) |
Aug 19, 2026 9w ago | DEFA14A | $1.17 $1.12 | ▼ −4.27% | ▼ −2.32% | $0.9985 (−14.66%) |
Aug 10, 2026 11w ago | 8-K | $1.17 $1.19 | ▲ +1.71% | ▲ +2.62% | $0.9985 (−14.66%) |
Jun 15, 2026 19w ago | 8-K | $1.29 $1.24 | ▼ −3.88% | ▼ −3.13% | $0.9985 (−22.60%) |
Jun 8, 2026 20w ago | 8-K | $1.21 $1.24 | ▲ +2.48% | ▲ +1.03% | $0.9985 (−17.48%) |
Apr 24, 2026 26w ago | 8-K | $1.40 $1.30 | ▼ −7.14% | ▼ −11.17% | $0.9985 (−28.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers